Objective: The hybrid procedure of femoral endarterectomy and iliac artery stenting (FEIS) has been used as an alternative to traditional open surgical repair of iliofemoral arterial occlusive disease, but whether the severity of the iliac disease component affects long-term results is not well understood.
The combination of femoral endarterectomy and iliac artery stenting (FEIS) is an effective treatment for combined iliofemoral arterial occlusive disease. [1] [2] [3] In contrast to open surgical bypass, FEIS allows the iliac segment to be treated from the open femoral exposure with endovascular techniques, thus sparing the patient an abdominal incision, whether it is transperitoneal or retroperitoneal. Whether the severity of the iliac disease component affects the long-term patency after FEIS is not well understood. According to the current TransAtlantic Inter-Society Consensus (TASC II) classification system, the presence of associated common femoral artery disease in the setting of iliac disease of any severity would assign the patient to TASC C or D status.
For example, external iliac and common femoral disease is classified as TASC C; common iliac, external iliac, and common femoral disease is classified as TASC D. 4 However, the current TASC II guidelines do not account for the differences in severity of iliac disease in assigning TASC classification in the TASC C and D patients who have combined iliac artery and femoral artery disease.
On the basis of the available literature and our anecdotal experience, we hypothesized that the severity of the iliac disease component in combined iliofemoral arterial occlusive disease does not affect the long-term patency of FEIS. [1] [2] [3] 5, 6 We report our single-institution experience of FEIS in patients who are stratified according to the severity of the iliac disease component.
METHODS
This was a retrospective study of consecutive adult patients undergoing FEIS within the Geisinger Health System from January 1, 2004 , to December 31, 2013. Those patients who underwent the procedure concomitantly with an additional procedure (ie, abdominal aortic aneurysm repair or infrainguinal bypass) or for trauma were excluded from this study. Because this study was a retrospective chart review, informed consent was not required from each patient. The study was approved by the Institutional Review Board of Geisinger Medical Center. Diagnosis of iliofemoral arterial occlusive disease was based on clinical symptoms in combination with appropriate vascular imaging that included for each patient either computed tomography angiography or digital subtraction angiography. Patients were considered for treatment if they had claudication, rest pain, or tissue loss. No patients underwent treatment for asymptomatic disease. Patients were then stratified according to the severity of the iliac arterial occlusive disease component, acknowledging that by TASC II guidelines, all of the patients in our series had common femoral artery disease, which puts them automatically into a TASC C or D status. With the goal being to evaluate the influence of the severity of the iliac disease component and its effect on clinical outcome, patients were divided into two groups based on the severity of the iliac disease component: those with mild iliac disease (group 1) and those with advanced iliac disease (group 2). Mild iliac disease was defined as unilateral common iliac artery or external iliac artery stenosis, combined common iliac artery and external iliac artery stenosis <10 cm in length, or focal short-segment (<3 cm) common iliac artery or external iliac artery occlusion. Severe iliac disease was defined as combined common iliac artery and external iliac artery stenosis >10 cm in length or any common iliac artery or external iliac artery occlusion >3 cm in length. The status of the internal iliac artery was not considered in this study.
Femoral endarterectomy was performed at the discretion of the operating surgeon, and the extent of the endarterectomy was categorized on the basis of review of the operative notes. Patch angioplasty was routinely performed with either bovine pericardium or vein. Iliac stenting was performed through a sheath inserted into the patch over a wire after the endarterectomy, according to the discretion of the operating surgeon. Anticoagulation protocols were not standardized other than the administration of unfractionated heparin during the procedure at a dose of 80 to 100 units per kilogram of body weight, and activated clotting times were not routinely checked. All patients were prescribed lifelong aspirin therapy (81 mg orally daily) after the procedure, and selective patients were prescribed dual antiplatelet therapy with aspirin (81 mg orally daily) and clopidogrel (75 mg orally daily) at the discretion of the operating surgeon. During the time of this study, the surgeons were not strictly enforcing the use of high-dose statin therapy routinely. Postoperatively, patients were evaluated with clinical examination; duplex ultrasound of the infrarenal aorta, common iliac artery, external iliac artery, common femoral artery, profunda femoris artery, and superficial femoral artery; and ankle-brachial index examinations at 1 month, every 6 months for the next year, and then yearly thereafter.
Using data contained in the electronic medical record, demographic data as well as intraoperative and postoperative variables were collected for both groups. End points of the study were primary patency, primary assisted patency, secondary patency, limb salvage, and overall survival. Differences in categorical variables between groups were evaluated with Fisher exact testing or c 2 testing, where appropriate; primary end point outcomes in each group were displayed with Kaplan-Meier curves, and differences between curves were compared with log-rank testing. Univariate analysis was also performed to identify any preoperative or intraoperative variables that may be predictive of reconstruction failure. A P value of < .05 was considered statistically significant. Statistical analysis was performed using SAS version 9.4 software (SAS Institute, Cary, NC).
RESULTS
Between January 1, 2004, and December 31, 2013, there were 99 patients who underwent 111 FEIS procedures (34 limbs in group 1 and 77 limbs in group 2). Nine patients underwent staged bilateral procedures, and three patients underwent simultaneous bilateral procedures. Each limb was analyzed as a separate procedure. There was one patient in whom the iliac artery lesion could not be crossed; this patient underwent a femoralfemoral bypass and was excluded from data analysis. Table I shows demographic data between the group 1 and group 2 patients. Mean age and gender distribution were similar. Indications for surgery were claudication (41%), ischemic rest pain (36%), and tissue loss (23%). Group 2 patients had a statistically higher rate of smoking status and chronic obstructive pulmonary disease compared with group 1 patients; otherwise, the groups were similar. Table II shows intraoperative data comparing group 1 and group 2 patients. Length of surgery (group 1, 243 6 86 minutes; group 2, 290 6 94 minutes; P ¼ .01), estimated blood loss (group 1, 200 mL; group 2, 330 mL; P ¼ .03), and total intravenous fluids administered (group 1, 2145 6 739 mL; group 2, 2688 6 1137 mL; P ¼ .01) were significantly higher in group 2, suggesting a more challenging technical procedure in these patients. The type of stent used (self-expanding vs balloon-expandable stent) was also noted to be significantly different, Recommendation: The authors suggest that femoral endarterectomy combined with iliac artery stent placement is a durable procedure, and 5-year patency is not affected by the degree of iliac or femoral disease.
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with group 2 patients more often requiring a combination of multiple stent types (group 1, 18%; group 2, 40%; P ¼ .03). As might be expected, longer stent lengths were needed for group 2 patients (group 1, 60 mm; group 2, 80 mm; P ¼ .01), and more group 2 patients required stents in both the common and external iliac arteries (group 1, 32%; group 2, 61%; P ¼ .01). Finally, the extent of the femoral endarterectomy was also noted to be different, with a greater need to extend the endarterectomy proximally under the inguinal ligament into the distal external iliac artery in group 2 patients (group 1, 47.1%; group 2, 66.2%; P ¼ .06), although this did not reach statistical significance. No major differences were noted in the extent of the endarterectomy involving the common femoral artery, the superficial femoral artery, or the profunda femoris artery. Bovine pericardium was the preferred patch material, being used in 94% of group 1 patients and 100% of group 2 patients (P ¼ .99). No patients within this series required a postoperative intensive care unit admission. Length of stay was not different between the two groups, ranging from 1 to 4 days (P ¼ .15). Fig 1 shows that the primary patency, primary assisted patency, and secondary patency rates during the long term were similar between groups, although there was a trend toward better primary assisted patency rates in group 2 (P ¼ .06). Fig 2 shows that long-term amputation-free survival (limb salvage) was similar between groups (group 1, 90%; group 2, 92%; P ¼ .05). Fig 3 shows a noticeable trend toward increased overall mortality in group 2 (P ¼ .08), although this did not reach statistical significance. Table III describes univariate analysis for predictors of stent failure, defined as the need to perform a repeated noncovered stent, P ¼ 1.0; stent diameter, P ¼ .17; stent length, P ¼ .78; or location of stent in common iliac artery vs external iliac artery vs both, P ¼ .11). Presentation with the hallmark symptoms of critical limb ischemia (rest pain, gangrene, and ulcers) was also found to confer an increased risk for stent failure (hazard ratio, 4.0). However, there was no difference in the risk of stent failure between group 1 and group 2 patients (P ¼ .72). A summary of the various types of stents used is provided in Table IV .
The most common type of stent used was a covered selfexpanding stent.
DISCUSSION
In their initial report of FEIS in 2002, Nelson et al 1 studied the results of patients treated with femoral endarterectomy and external iliac artery stenting. Although TASC classification was not reported in that series, the patients in that series would be considered today to have had TASC C disease. The same group updated their results in a report in 2008, looking also at patients with TASC D disease, which included patients with combined common iliac, external iliac, and common femoral disease. 2 The primary assisted patency rate was 97% at 1 year in the first report and 97% at 5 years in the second report, strongly suggesting that there is no difference in patency rates between TASC C and D lesions, although the two groups were not directly compared in either study. Our results suggest that there is no difference in the long-term patency rates and limb salvage rates between patients with mild iliac disease and patients with advanced iliac disease who undergo FEIS for combined iliofemoral arterial occlusive disease. Although patients with advanced iliac disease in our series did require longer operative times and sustained higher intraoperative blood loss, it did not translate into increased length of stay or decreased patency. The operative times were longer presumably owing to the more severe disease burden that required more frequent extension of the endarterectomy proximally onto the external iliac artery, a greater use of a combination of both balloonexpandable and self-expanding stents, and a more frequent use of a combination of both covered and bare-metal stents. In short, as one might expect, reconstructions were technically more demanding in the patients with severe iliac artery disease.
The trend toward increased mortality in the group 2 patients is noteworthy, and if the follow-up in our series were longer, it very well may have reached statistical significance. We suspect, however, that the study was underpowered to detect a statistically significant difference at 5 years. However, the increased rates of tobacco exposure and lung disease in the group 2 patients could easily explain a trend toward earlier mortality in this population of patients. It is unlikely that the longer operative times played a role in the long-term mortality trend. When comparing predictors of stent failure using univariate analysis, we did not find any device-related factors that influenced patency; thus, multivariate analysis was not performed. In our series, the use of selfexpanding stents vs balloon-expandable stents vs both had no effect on patency, and the use of covered stents vs noncovered stents vs both had no effect on patency. Admittedly, our study was not designed to evaluate these differences and is likely underpowered to make any firm conclusions. In contrast, when Chang et al 2 published their series from 2008, a subgroup analysis of their data suggested a higher patency rate when covered stents were used in the iliac arteries. Interestingly, in a study by Humphries et al 7 in 2014 looking strictly at percutaneous iliac artery interventions, the use of covered balloon-expandable stents conferred a reduction in patency rates compared with bare-metal balloon-expandable stents. In two separate series by Piazza et al 8 and Psacharopulo et al, 9 it was demonstrated that covered stents for severe iliac lesions had (Continued on next page) patency rates similar to those of bare-metal stents. However, when both of these groups of investigators looked specifically at long-segment TASC D lesions, covered stents actually had better patency rates than baremetal stents in this subgroup of patients. In the initial report of the Covered vs Balloon Expandable Stent Trial (COBEST) in 2011, there was a reduction in the incidence of restenosis in patients treated with covered stents. 10 Most recently, the COBEST investigators reported 5-year follow-up results, which continued to demonstrate a patency advantage for the covered stents; however, most of the patients in each group were TASC B status, so whether the same findings would hold true in more advanced TASC C/D iliac lesions remains less well defined. 11 Although the bulk of the evidence to date would favor covered stents for the treatment of iliac arterial occlusive disease, the data from most of these studies have been strictly from patients undergoing percutaneous isolated iliac artery interventions, not the combined procedure of FEIS. Thus, we cannot make direct comparisons between our study and those mentioned before. It is safe to assume that additional work is necessary to determine the optimal stent type to be used for the iliac component of FEIS.
Our study has several limitations. First, it is a retrospective study from a single health care system, and results may not be generalizable across the vascular community. The surgeon's selection of patients, heterogeneity in performing the technical portions of the operations, and lack of standardized medical regimens may have influenced the results. The extent of the endarterectomy, the type of stent used, and the postoperative medical management were all left to the discretion of the operating surgeon; thus, a certain degree of bias may have resulted. Because of small numbers in each group, it is possible that other differences in outcome exist but were missed because of the study's being underpowered. Last, because of the retrospective nature of the study, important clinical events may have been missed.
CONCLUSIONS
In the treatment of iliofemoral arterial occlusive disease using FEIS, the severity of the iliac occlusive disease component does not appear to affect long-term durability as patency rates and limb salvage rates are similar between patients with mild iliac disease and patients with severe iliac disease during long-term follow-up. The optimal type of stent to use for the iliac stenting component of FEIS remains to be well defined. Note that the totals are greater than the number of limbs treated because of multiple limbs receiving more than one stent.
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